The Swedish BioFINDER Study
The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.
News articles
Blood Tests: Not Just for the Impaired?
In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease...
Read more...Looking Good: Immunoassays for Blood Markers
For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical...
Read more...
Recent key publications
- 16 September, 2025
Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers
- 15 September, 2025
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
- 12 August, 2025
Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification
- 25 July, 2025
Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings
X posts
New paper out in EMBO Mol Med! We use machine learning to predict Aβ-PET burden from fluid biomarkers
Findings:
-Performance R² = 0.79
-CSF Aβ42/Aβ40 most predictive of Aβ plaque presence
-Plasma p-tau217 best for tracking increasing amyloid plaque burden
Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated...
imageimageMachine-learning models using CSF and plasma biomarkers accurately predicted quantitative Aβ-PET burden. Distinct ...
www.embopress.org
Main takeaway:
CSF Ab42/Ab40 and plasma p-tau217 showed distinct contributions when predicting Aβ-PET, improving our understanding of disease progression and guiding how biomarkers can be applied in clinical and research settings.
The study was led by @NiklasMattsson4, @karlssonlinda1, and Weizhong Tang. Thank you to all co-authors: Kaj Blennow, Henrik Zetterberg, @RandallBateman3, @SuzanneESchind1, Nicolas Barthelemy, @SebastianPalmqv, @EStomrud, Shorena Janelidze, and @OskarHansson9.
🚨Paper Out in @EANeurology!
Systematic Review & Meta-analysis of ALS Fluid Biomarkers
🧵Key findings:
• NfL leads for both diagnosis (AUC 0.81–0.92) & prognosis (HR 2.8–4.3)
• CSF chitinases, p-tau/t-tau: moderate values
• Marked heterogeneity
🔗
Diagnostic and Prognostic Value of Blood and Cerebrospinal Fluid Biomarkers in Amyotrophic Lateral...
Background Reliable biomarkers for amyotrophic lateral sclerosis (ALS) are urgently needed due to diagnostic and prognos...
doi.org
💡 Takeaway:
• NfL is robust but not sufficient alone in low-prevalence settings.
• Diagnostic and prognostic frameworks should move toward standardized multimodal models integrating fluid #biomarkers with established predictors.
#ALS #MND
🚨New publication in Alzheimer's & Dementia! In this perspective paper, we discuss whether Aβ blood biomarkers can replace the accepted reference standard, Aβ-PET, for assessing Aβ burden.🔗Full paper:
Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and...
With the rapid development of blood biomarkers (BBMs) related to amyloid-β (Aβ) pathology in Alzheimer's disease (AD...
alz-journals.onlinelibrary.wiley.com
A huge thanks to all authors: @LECollij, @NiklasMattsson4, Shorena Janelidze, @RikOssenkoppele, and @OskarHansson9